27237-21-4

Upstream product

• 2303-25-5 3-methyl-4'-nitrodiphenyl ether 
• 284462-55-1 ethyl 3-(4'-nitrophenoxy)benzoate 
• 99-06-9 3-Carboxyphenol 
• 100-00-5 4-chlorobenzonitrile 
• 350-46-9 4-Fluoronitrobenzene 
• 7781-98-8 ethyl-3-hydroxybenzoate 
• 108-39-4 3-methyl-phenol 

Downstream Products

• 71708-64-0 N-methyl-3-(4-nitrophenoxy)benzamide 
• 54579-63-4 4-(3-carboxyphenoxy)aniline 
• 284462-55-1 ethyl 3-(4'-nitrophenoxy)benzoate 
• 1253119-88-8 2-(2,5-bis(hexyloxy)-4-(5-(3-(4-nitrophenoxy)phenyl)-1,3,4-oxadiazole-2-yl)phenyl)-5-(4-t-butylphenyl)-1,3,4-oxadiazole 
• 1253119-89-9 2-(5-(4-t-butylphenyl)-1,3,4-oxadiazole-2-yl)-5-(5-(3-(4-nitrophenoxy)phenyl)-1,3,4-oxadiazole-2-yl)benzene-1,4-diol 
• 1253119-90-2 2-(5-(3-(4-aminophenoxy)phenyl)-1,3,4-oxadiazole-2-yl)-5-(5-(4-t-butylphenyl)-1,3,4-oxadiazole-2-yl)benzene-1,4-diol 
• 1253119-93-5 5,5'-(2,5-bis(hexyloxy)-1,4-phenylene)bis(2-(3-(4-nitrophenoxy)phenyl)-1,3,4-oxadiazole) 
• 1253119-94-6 2,5-bis(5-(3-(4-nitrophenoxy)phenyl)-1,3,4-oxadiazole-2-yl)benzene-1,4-diol 
• 1253119-95-7 2,5-bis(5-(3-(4-aminophenoxy)phenyl)-1,3,4-oxadiazole-2-yl)benzene-1,4-diol 
• 1253119-87-7 N'-1-(4-t-butylbenzoyl)-2,5-bis(hexyloxy)-N'-4-(3-(4-nitrophenoxy)benzoyl)terephthalohydrazide 
• 1253119-91-3 2-(5-(4-t-butylphenyl)-1,3,4-oxadiazole-2-yl)-5-(5-(3-(4-(2-(2-hydroxyphenyl)-4,5-diphenyl-1H-imidazole-1-yl)phenoxy)phenyl)-1,3,4-oxadiazole-2-yl)benzene-1,4-diol 
• 1253119-92-4 2,5-bis(hexyloxy)-N'1,N'4-bis(3-(4-nitrophenoxy)benzoyl)terephthalohydrazide 
• 1383627-70-0 3-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N,N-dimethylbenzamide 
• 41370-84-7 3-(4-nitrophenoxy)benzoyl chloride 

Relevant academic research and scientific papers

Synthesis and properties of 1,3,4-oxadiazole-containing bismaleimides with asymmetric structure and the copolymerized systems thereof with 4,4′-bismaleimidodiphenylmethane

Two novel bismaleimide monomers containing 1,3,4-oxadiazole and asymmetric structure, i.e., 2-[4-(4-maleimidophenoxy)phenyl]-5-(4-maleimidophenyl)-1,3,4- oxadiazole (p-Mioxd) and 2-[3-(4-maleimidophenoxy)phenyl]-5-(4-maleimidophenyl)- 1,3,4-oxadiazole (m-Mioxd), were designed and synthesized. The chemical structures of the monomers were confirmed using Fourier transform infrared spectroscopy (FTIR), 1H NMR and 13C NMR spectroscopy and elemental analysis. The thermal properties of the monomers were investigated by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). The results indicate that the incorporation of the 1,3,4-oxadiazole and asymmetric structure could improve the solubility and processability of the BMI monomers and the thermal stability of the resins. Composites composed of glass cloth and 4,4′-bismaleimidodiphenylmethane (BMDM), which were modified with 2.5, 5 and 10 wt% p-Mioxd and m-Mioxd, respectively, were also prepared. The TGA and DMA results demonstrate that the resulting composites have excellent thermal stability with high residual weight percentage at 700 °C (>45%) and Tg (>450 °C).

Life beyond kinases: Structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors

Of great interest in recent years has been computationally predicting the novel polypharmacology of drug molecules. Here, we applied an "induced-fita€ protocol to improve the homology models of 5-HT2A receptor, and we assessed the quality of these models in retrospective virtual screening. Subsequently, we computationally screened the FDA approved drug molecules against the best induced-fit 5-HT2A models and chose six top scoring hits for experimental assays. Surprisingly, one well-known kinase inhibitor, sorafenib, has shown unexpected promiscuous 5-HTRs binding affinities, Ki = 1959, 56, and 417 nM against 5-HT 2A, 5-HT2B, and 5-HT2C, respectively. Our preliminary SAR exploration supports the predicted binding mode and further suggests sorafenib to be a novel lead compound for 5HTR ligand discovery. Although it has been well-known that sorafenib produces anticancer effects through targeting multiple kinases, carefully designed experimental studies are desirable to fully understand whether its "off-targeta€ 5-HTR binding activities contribute to its therapeutic efficacy or otherwise undesirable side effects.

WHITE-EMITTING COMPOUNDS USING EXCITED-STATE INTRAMOLECULAR PROTON TRANSFER, ORGANIC ELECTROLUMINESCENT ELEMENT AND LASER MATERIAL USING THE SAME

Provided are a white-emitting monomolecular compound using excited-state intramolecular proton transfer (ESIPT) characteristics, and an organic electroluminescence device and a laser device comprising same. The white-emitting monomolecular compound according to the present invention is prepared by covalently bonding at least two types of molecules which produce different colors and have excited-state intramolecular proton transfer (ESIPT) characteristics. The white-emitting monomolecular compound according to the present invention achieves white luminescence irrespective of the concentration thereof and of the state of the materials thereof, and therefore can be used in a variety of fields including an organic electroluminescence device and a laser device.

Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.

Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors

This invention relates to the use of a group of heteroaryl ureas containing nitrogen in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.

Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Process for preparing nitrodiphenyl (thio) ethers

Nitrodiphenyl(thio) ethers in which the nitro group is in the ortho- or para-position with respect to the ether oxygen or ether sulphur can be prepared from halonitrobenzones in which the nitro group is in the ortho- or para-position with respect to the halogen and, alkali metal (thio)phenolates in liquid ammonia, the reaction being carried out under pressure and at a temperature from -30° C. to +140° C. and the ammonia being separated off after the reaction is completed.